2′-Fluoro-2′-Deoxycytidine Inhibits Borna Disease Virus Replication and Spread

Bajramović, Jeffrey J.; Volmer, Romain; Syan, Sylvie; Pochet, Sylvie; Gonzalez–Dunia, Daniel

doi:10.1128/aac.48.4.1422-1425.2004

Cited by 15 publications

(5 citation statements)

References 26 publications

(20 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…is a nucleoside inhibitor used in anticancer drugs. It inhibits various RNA and DNA viruses in vitro, such as Borna virus (Bajramovic et al, 2004), Lassa virus (Welch et al, 2016), Crimean-Congo hemorrhagic fever virus (Welch et al, 2017), influenza virus (Kumaki et al, 2011), and herpesviruses (Wohlrab et al, 1985). Smee et al (2018) has shown the antiviral activity of 2 ′ -FdC against various bunyaviruses, such as La Crosse virus, Maporal virus, Punta Toro virus, Rift Valley fever virus, San Angelo virus, Heartland virus, and SFTSV.…”

Section: Calcium Channel Blockersmentioning

confidence: 99%

Antiviral Drugs Against Severe Fever With Thrombocytopenia Syndrome Virus Infection

Takayama-Ito

Saijo

2020

Front. Microbiol.

View full text Add to dashboard Cite

Severe fever with thrombocytopenia syndrome (SFTS) is an emerging tick-borne infectious disease caused by SFTS virus (SFTSV), which is a novel bunyavirus. SFTSV was first isolated from patients who presented with fever, thrombocytopenia, leukocytopenia, and multiorgan dysfunction in China. Subsequently, it was found to be widely distributed in Southeast Asia (Korea, Japan, and Vietnam). SFTSV can be transmitted not only from ticks but also from domestic animals, companion animals, and humans. Because the case fatality rate of SFTS is high (6-30%), development of specific and effective treatment for SFTS is required. Studies of potential antiviral drugs for SFTS-specific therapy have been conducted on existing or newly discovered agents in vitro and in vivo, with ribavirin and favipiravir being the most promising candidates. While animal experiments and retrospective studies have demonstrated the limited efficacy of ribavirin, it was also speculated that ribavirin would be effective in patients with a viral load <1 × 10 6 copies/mL. Favipiravir showed higher efficacy than ribavirin against SFTSV in in vitro assays and greater efficacy in animal models, even administrated 3 days after the virus inoculation. Although clinical trials evaluating the efficacy of favipiravir in SFTS patients in Japan are underway, this has yet to be confirmed. Other drugs, including hexachlorophene, calcium channel blockers, 2 ′ -fluoro-2 ′ -deoxycytidine, caffeic acid, amodiaquine, and interferons, have also been evaluated for their inhibitory efficacy against SFTSV. Among them, calcium channel blockers are promising because in addition to their efficacy in vitro and in vivo, retrospective clinical data have indicated that nifedipine, one of the calcium channel blockers, reduced the case fatality rate by >5-fold. Although further research is necessary to develop SFTS-specific therapy, considerable progress has been achieved in this area. Here we summarize and discuss recent advances in antiviral drugs against SFTSV.Keywords: severe fever with thrombocytopenia syndrome, severe fever with thrombocytopenia syndrome virus, antiviral, ribavirin, favipiravir Frontiers in Microbiology | www.frontiersin.org

show abstract

Section: Calcium Channel Blockersmentioning

confidence: 99%

Antiviral Drugs Against Severe Fever With Thrombocytopenia Syndrome Virus Infection

Takayama-Ito

Saijo

2020

Front. Microbiol.

View full text Add to dashboard Cite

show abstract

“…However, its use is compromised by side effects. Some other antivirals have also been developed against BDV, but these trials have so far remained in the initial phase (Planz et al, 2001;Bajramovic et al, 2004;Volmer et al, 2005;Qian et al, 2010).…”

Section: Treatment and Prevention Of Bdmentioning

confidence: 99%

Epidemiology and host spectrum of Borna disease virus infections

Kinnunen

Palva

Vaheri

et al. 2013

Journal of General Virology

View full text Add to dashboard Cite

Borna disease virus (BDV) has gained lot of interest because of its zoonotic potential, ability to introduce cDNA of its RNA transcripts into host genomes, and ability to cause severe neurobehavioural diseases. Classical Borna disease is a progressive meningoencephalomyelitis in horses and sheep, known in central Europe for centuries. According to current knowledge, BDV or a close relative also infects several other species, including humans at least occasionally, in central Europe and elsewhere, but the existence of potential ‘human Borna disease’ with its suspected neuropsychiatric symptoms is highly controversial. The recent detection of endogenized BDV-like genes in primate and various other vertebrate genomes confirms that at least ancient bornaviruses did infect our ancestors. The epidemiology of BDV is largely unknown, but accumulating evidence indicates vectors and reservoirs among small wild mammals. The aim of this review is to bring together the current knowledge on epidemiology of BDV infections. Specifically, geographical and host distribution are addressed and assessed in the critical light of the detection methods used. We also review some salient clinical aspects.

show abstract

“…It is noteworthy that 2′-fluoro-2′-deoxycytosine (FdC) ( 6-6a) was found to be a potent anti-HCV agent with EC 90 value of 5 μM, which is more potent than ribavirin, an FDA approved anti-HCV drug [18]. FdC ( 6-6a) also exhibits potent antiviral activity against Borna disease virus (BDV) [19]. …”

Section: Synthesis Of Carbohydrate Fluorinated Nucleosidesmentioning

confidence: 99%